https://itftherapeutics.com/community-letter/actualizacion-sobre-el-desarrollo-de-duvyzat-givinostat-para-el-tratamiento-de-la-dmd/ 2026-02-26T17:05:37+00:00 https://itftherapeutics.com/community-letter/itf-therapeutics-llc-announces-commercial-availability-of-duvyzat-givinostat-for-the-treatment-of-duchenne-muscular-dystrophy/ 2026-02-26T17:14:31+00:00 https://itftherapeutics.com/community-letter/itf-therapeutics-llc-anuncia-la-disponibilidad-comercial-de-duvyzat-givinostat-para-el-tratamiento-de-la-distrofia-muscular-de-duchenne/ 2026-02-26T17:21:46+00:00 https://itftherapeutics.com/community-letter/an-exciting-update-on-the-long-term-use-of-duvyzat/ 2026-02-26T17:28:25+00:00 https://itftherapeutics.com/community-letter/a-meaningful-milestone-made-possible-together/ 2026-02-26T17:33:05+00:00 https://itftherapeutics.com/community-letter/new-data-presented-on-duvyzat-givinostat-at-2025-nmsg-annual-scientific-meeting/ 2026-05-06T16:40:37+00:00 https://itftherapeutics.com/community-letter/update-on-development-of-duvyzat-givinostat-for-treatment-of-dmd/ 2026-05-26T10:55:27+00:00 https://itftherapeutics.com/community-letter/new-data-and-analyses-presented-on-duvyzat-givinostat-at-2026-mda-clinical-and-scientific-conference/ 2026-06-16T13:56:09+00:00